Translating ADA/EASD Guidelines and the ACE/AACE Road Maps into Primary Care of Patients with Type 2 Diabetes

Journal for Nurse Practitioners

Volumn 4, Issue 9, 2008, Pages 661-671

  Robertson, Carolyn ^a  

^a NONE

Author keywords

A1C; glycemic control; management guidelines; Type 2 diabetes

Indexed keywords

EID: 53649091309     PISSN: 15554155     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurpra.2008.01.016     Document Type: Article

References (48)

1. Goldfarb B. ACE and AACE Issue Treat-to-Target road map. DOC News 2 (2005) 11
2. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States (2007), US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA 2007
3. National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics fact sheet: general information and national estimates on diabetes in the United States (2007), US Department of Health and Human Services, National Institutes of Health, Bethesda, MD. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/ Accessed August 4, 2008.
4. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
5. American Diabetes Association. Standards of Medical Care in Diabetes - 2008. Diabetes Care 31 Suppl 1 (2008) S13-S54
6. Lebovitz H.E., Austin M.M., Blonde L., et al. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 12 Suppl 1 (2006) 6-12
7. Davis W.A., Bruce D.G., and Davis T. Is self monitoring of blood glucose appropriate for all Type 2 diabetic patients? The Fremantle diabetes study. Diabetes Care 29 (2006) 1764-1770
8. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 29 (2006) 1963-1972
9. Jellinger P.S., Davidson J.A., Blonde L., et al. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract 13 (2007) 260-268
10. The United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352 (1998) 837-853
11. The United Kingdom Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352 (1998) 854-865
12. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 321 (2000) 405-412
13. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. (Finnish Diabetes Prevention Study Group). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
14. Knowler W.C., Barratt-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
15. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
16. DECODE Study Group, and European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 26 (2003) 688-696
17. Esposito K., Giugliano D., Nappo F., et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110 (2004) 214-219
18. Genuth S. Insights from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study on the use of intensive glycemic treatment to reduce the risk of complications of type I diabetes. Endocr Pract 12 Suppl 1 (2006) 34-41
19. Hanefeld M., Koehler C., Schaper F., et al. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 144 (1999) 229-235
20. Hanefeld M., and Temelkova-Kurktschiev T. Control of post-prandial hyperglycemia - an essential part of good diabetes treatment and prevention of cardiovascular complications. Nutr Metab Cardiovasc Dis 12 (2002) 98-107
21. Nathan D.M., Cleary P.A., Cacklund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type I diabetes. N Engl J Med 353 (2005) 2642-2653
22. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomizedprospective 6-year study. Diabetes Res Clin Pract 28 (1995) 103-117
23. Khaw K.T., Wareham N., Luben R., et al. Glycated haemoglobin, diabetes, and mortality in men in the Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 322 (2000) 15-18
24. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
25. Lincoff M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
26. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
27. Solomon D.H., and Winkelmayer W.C. Cardiovascular risk and the thiazolidinediones: déjà vu all over again?. JAMA 298 (2007) 1216-1218
28. Lago R.M., Singh P., and Nesto R. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370 (2007) 1129-1136
29. Home P.D., Pocock S.J., Beck-Nielsen H., et al., for the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
30. Siebolds M., Gaedeke O., and Schwede U. Self-monitoring of blood glucose - psychological aspects relevant to changes in HbA1c in type 2 diabetic patients treated with diet or diet plus oral antidiabetic medication. Patient Educ. Couns. 62 (2006) 104-110
31. Welschen L.M.C., Bloemendal E., Nijpels G., et al. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database of Syst Rev (2005) 10.1002/14651858.CD005060.pub2 Issue 3. Art. No.: CD005060
32. Schwedes U., Siebolds M., and Mertes G. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care 25 (2002) 1928-1932
33. Rohlfing C.L., Wiedmeyer H.M., Little R.R., et al. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 25 (2002) 275-278
34. American Diabetes Association. Postprandial blood glucose (Consensus Statement). Diabetes Care 24 (2001) 775-778
35. Meneghini L.F., Rosenberg K.H., Koenen C., et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naïve or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 9 (2007) 418-427
36. Hirsch I.B. Type 1 diabetes mellitus and the use of flexible insulin regimens. Am Fam Physician 60 (1999) 2343-2352 2355-2356.
37. Hermansen K., Fontaine P., Kukolja K.K., et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47 (2004) 622-629
38. Raslova K., Tamer S.C., Clauson P., et al. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 27 (2007) 279-285
39. Home P., and Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 7 (2006) 325-343
40. Riddle M.C., Rosenstock J., and Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
41. Kulzer B., Hermanns N., Reinecker H., and Haak T. Effects of self-management training in type 2 diabetes: a randomized, prospective trial. Diabet Med 24 (2007) 415-423
42. Jorgens V. [Cost-benefit analysis of education programs and of treatment in type 2 diabetes] [Article in French]. Diabetes Metab 19 5 Suppl (1993) 510-513
43. Strine T.W., Okoro C.A., Chapman D.P., et al. The impact of formal diabetes education on the preventive health practices and behaviors of persons with type 2 diabetes. Prev Med 41 (2005) 79-84
44. Deakin T., McShane C.E., Cade J.E., and Williams R.D. Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2 (2005) CD003417.
45. Ko S.H., Song K.H., Kim S.R., et al. Long-term effects of a structured intensive diabetes education programme (SIDEP) in patients with type 2 diabetes mellitus - a 4-year follow-up study. Diabet Med 24 (2007) 55-62
46. Wagner E.H. Chronic disease management: what will it take to improve care for chronic illness?. Eff Clin Pract 1 (1998) 2-4
47. Wagner E.H., Austin B.T., Davis C., et al. Improving chronic illness care: translating evidence into action. Health Aff (Millwood) 20 (2001) 64-78
48. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105